


## LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **saxagliptin** (DPP-4 inhibitors)
- Comparator (class): **glyburide** (Sulfonylureas)
- Outcome: **Bladder cancer**

### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	1,157	1,343	0	0.00
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	46,122	35,861	42	1.17
Merative CCAE	0	0	0	-
Merative MDCD	-	-	-	-
Merative MDCR	1,451	1,368	<5	<3.65
Optum Clinformatics	6,476	5,714	5	0.87
Optum EHR	5,291	1,880	<5	<2.66
Veterans Affairs	0	0	0	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)

